Astrazeneca PLC stock price

Astrazeneca PLC latest news:


  • 09/14/2017 14:48:30

    BRIEF-Flexion Therapeutics says co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​

    * Flexion Therapeutics Inc - ‍on September 8, co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​

  • 09/10/2017 23:51:36

    UK Stocks-Factors to watch on Sept 11

    Sept 11 (Reuters) - Britain's FTSE 100 index is seen opening up 28 points at 7,405 on Monday, according to financial bookmakers. * AstraZeneca: Two AstraZeneca drugs tackling lung cancer in different ways delivered encouraging results on Saturday, helping the British group offset July's big clinical trial setback in the disease. * SHELL: Shell's Nigerian business has signed a $300 mln deal with Shoreline Energy to develop gas pipeline infrastructure in the country, Financial Ti

  • 09/09/2017 09:04:15

    AstraZeneca CEO, worried by Brexit, not signing UK government letter

    MADRID (Reuters) - AstraZeneca Chief Executive Pascal Soriot, fearing a potentially abrupt Brexit, said on Saturday that lack of progress in negotiations made it impossible for him to sign a public letter of support for the British government's strategy.

  • 09/08/2017 16:46:38

    AstraZeneca shares tick higher on lung cancer drug study results

    U.S. shares of AstraZeneca PLC rose in the extended session Friday after the drug maker released promising results from a lung cancer drug study. AstraZeneca American depositary receipts rose 2% to $32.90 after hours. The company said a late-stage clinical trial of its drug Tagrisso improved progression-free survival rates in certain lung cancer patients to a median 18.9 months compared with the 10.2 months seen in patients given standard of care treatment.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/06/2017 23:36:22

    UK Stocks-Factors to watch on Sept 7

    Sept 7 (Reuters) - Britain's FTSE 100 index is seen opening 10 points higher at 7354.13 on Thursday, according to financial bookmakers. * RBS: Britain's financial regulator should release a leaked report about Royal Bank of Scotland that alleged many companies suffered from "inappropriate action" by its Global Restructuring Group unit, a senior British lawmaker said. * ASTRAZENECA: A new kind of injectable biotech treatment for severe asthma from AstraZeneca and Amgen promises t

  • 08/07/2017 12:15:00

    3 High-Yield Stocks for Aggressive Investors

    The high-yield dividend stocks AstraZeneca plc, GameStop, and Las Vegas Sands may be worth checking out right now.

  • 08/01/2017 00:38:12

    AstraZeneca gets breakthrough status for blood cancer drug

    LONDON, Aug 1 (Reuters) - AstraZeneca said on Tuesday that U.S. regulators had awarded its blood cancer drug acalabrutinib "breakthrough" status for the treatment of patients with mantle cell lymphoma, a rare type of blood cancer.

  • 07/31/2017 00:36:15

    AstraZeneca drug gets breakthrough status in early lung cancer

    AstraZeneca(AZN) said on Monday its immunotherapy drug Imfinzi had been granted "breakthrough" designation by U.S. regulators for treating non-metastatic lung cancer, following the success of the so-called Pacific trial.

  • 07/27/2017 15:15:31

    Facebook and Verizon advance while AstraZeneca dives

    Facebook and Verizon Communications trade higher while AstraZeneca and Southwest Airlines drop

  • 07/27/2017 10:43:43

    UPDATE 3-Bristol-Myers shares slump after failed AstraZeneca drug trial

    July 27 (Reuters) - Bristol-Myers Squibb Co shares fell 4 percent on Thursday as investors bet that a failed cancer-drug trial at AstraZeneca Plc would have negative implications for Bristol-Myers' similar immunotherapy treatment regimen.

  • 07/27/2017 01:34:42

    AstraZeneca revenue down as key drugs lose patent protection

    Anglo-Swedish drugmaker AstraZeneca says second-quarter revenue fell amid declining sales of blockbuster drugs Crestor and Seroquel XR, which lost patent protection in the United States last year

  • 07/27/2017 01:28:18

    BRIEF-Astrazeneca says establish strategic oncology collaboration with Merck

    Astrazeneca Plc(AZN): * ASTRAZENECA AND MERCK ESTABLISH STRATEGIC ONCOLOGY COLLABORATION. * Astrazeneca Plc(AZN) - ASTRAZENECA AND MERCK WILL INDEPENDENTLY DEVELOP AND COMMERCIALISE LYNPARZA AND POTENTIAL MEDICINE SELUMETINIB IN COMBINATIONS WITH COMPANIES' RESPECTIVE. * MERCK WILL PAY CO UP TO $8.5 BILLION IN TOTAL CONSIDERATION.

  • 07/27/2017 01:27:20

    AstraZeneca drags down FTSE 100

    The drugmaker is the biggest loser on the index after its share price falls more than 15%.

  • 07/27/2017 00:33:33

    AstraZeneca lung cancer study fails in big setback for company

    AstraZeneca's(AZN) combination of two immunotherapy drugs, durvalumab and tremelimumab, failed to help patients as hoped in a closely watched advanced lung cancer trial, the British company said on Thursday.

  • 07/27/2017 00:33:15

    UPDATE 1-AstraZeneca lung cancer study fails in big setback for company

    LONDON, July 27 (Reuters) - AstraZeneca's combination of two immunotherapy drugs, durvalumab and tremelimumab, failed to help patients as hoped in a closely watched advanced lung cancer trial, the British company said on Thursday.

  • 07/27/2017 00:19:17

    AstraZeneca lung cancer drug combination misses goal in key study

    LONDON, July 27 (Reuters) - AstraZeneca's combination of two immunotherapy drugs, durvalumab and tremelimumab, failed to help patients as hoped in a closely watched advanced lung cancer trial, the British company said on Thursday. (Reporting by Ben Hirschler)

  • 07/14/2017 14:34:56

    AstraZeneca says CEO Pascal Soriot will host earnings call

    Anglo-Swedish pharmaceutical firm AstraZeneca (AZN) said on Friday its chief executive, Pascal Soriot, would host a results call with reporters on July 27, after refusing to comment on speculation this week that he was leaving the firm.

  • 07/14/2017 14:32:21

    UPDATE 2-AstraZeneca says CEO Pascal Soriot will host earnings call

    LONDON, July 14 (Reuters) - Anglo-Swedish pharmaceutical firm AstraZeneca said on Friday its chief executive, Pascal Soriot, would host a results call with reporters on July 27, after refusing to comment on speculation this week that he was leaving the firm.

  • 07/14/2017 13:07:56

    AstraZeneca offers no comment after report saying CEO staying

    LONDON, July 14 (Reuters) - Anglo-Swedish pharmaceutical firm AstraZeneca declined to comment on speculation about the future of its chief executive Pascal Soriot on Friday, after a report quoted Bloomberg news agency saying he would stay in his post.

  • 07/12/2017 13:18:57

    AstraZeneca's CEO Soriot to join Israeli drugs company Teva-report

    Israel-based Teva Pharmaceutical Industries (TEVA) will name AstraZeneca (AZN) chief executive Pascal Soriot as its next CEO, the Calcalist financial news website said on Wednesday. Soriot has met with Teva representatives and expressed his agreement to serve as its next CEO.

  • More trends:

    AT&T Inc.T | Atento S.A.ATTO | Atlantic Power CorporationAT | Atlas EnergyATLS | Atlas Resource PartnersARP | Atlas Resource PartnersARP^D | Atlas Resource PartnersARP^E | Atmos Energy CorporationATO | Atwood OceanicsATW | AU Optronics CorpAUO |